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Coligation of the Hepatitis C Virus Receptor CD81 with
CD28 Primes Naive T Lymphocytes to Acquire Type 2
Effector Function1
Alessandro Serra,2* Sandra Nuti,* Simona Tavarini,* Chiara Sammicheli,* Domenico Rosa,*
Giulietta Saletti,* Elisabetta Soldaini,* Sergio Abrignani,† and Andreas Wack3*
Costimuli provide supplementary signals required by naive T cells to become fully activated upon Ag encounter. Tetraspanins are
a large family of transmembrane proteins that can costimulate T cells when engaged in vitro. In this study, we describe for the
first time that coligation of the tetraspanins CD81, CD82, or CD9 with the costimulatory molecule CD28 in vitro leads to pro-
liferation of naive T cells. When activated through this pathway, both CD4 and CD8 naive T cells differentiate into type 2
effector cells, which produce IL-4, IL-5, IL-13, and IL-10, together with IL-2 and TNF-, but little to no IFN-. These effector cells
descend from precursors that display early and strong production of IL-4, STAT6 phosphorylation, and up-regulation of the
transcription factor GATA-3, suggesting a direct skewing toward Th2 differentiation without a Th0 intermediate. The hepatitis
C virus envelope protein E2 is the only ligand known for CD81. Therefore, we propose that this new type of Ag-independent T
cell activation may occur in hepatitis C virus-infected individuals, contributing to liver inflammation, impaired type 1 immune
responses, and recurrent flares of type 2 immunity associated with chronic infection. The Journal of Immunology, 2008, 181:
174–185.
I t is well established that naive T lymphocytes require at leasttwo distinct signals to undergo full activation and differen-tiate into effector or memory cells (1). The first signal is
induced by triggering of the TCR by MHC:peptide complexes,
while the second can be mediated by engagement of surface mol-
ecules such as CD28, CD2, LFA-1, and CD49d (2–5).
Recently, a family of membrane proteins known as tetraspanins,
which among its members includes CD9, CD37, CD81, CD82, and
CD151, have been shown to participate in the process of T cell
costimulation (6). One tetraspanin in particular, CD81, is involved
in the aggregation of TCR and BCR signaling complexes (7–9)
and appears to play a critical role in the development of type 2
adaptive immune responses (10–12).
Whereas the ligands for most tetraspanins are still unknown,
CD81 has been shown to act as one of the receptors for hepatitis
C virus (HCV)4 upon recognition by the viral envelope protein E2
(HCV-E2) (13). This pathogen is an enveloped positive strand
RNA virus that infects the liver of humans and higher primates,
causing a life-long chronic inflammatory disease characterized by
severe immunopathology and increased risk of development of
hepatocellular carcinoma. Only 30% of individuals spontaneously
recover, and it is estimated that 3% of the world population is
affected (14–16).
Immunologic studies on rare self-healing patients suggest a strong
association between HCV elimination and strong and maintained im-
munity by CD4 and CD8 T cells that are capable of robust secre-
tion of IFN- upon recognition of a wide array of viral epitopes (17).
However, it is yet unclear what could be the factors that favor an
efficacious response. In this context, previous works suggest that dis-
ease chronicity may depend on an imbalance between type 1 and type
2 immunity, which has been described either as a lack of the former
(18–21) or an excess of the latter, distinguished by peripheral and
intrahepatic production of cytokines like IL-4 and IL-13 (22–25).
Several investigators addressed the question whether the inter-
action between HCV and one of its receptors might underlie a
successful strategy of immune evasion. Interestingly, although NK
cells are inhibited by the engagement of CD81 on their surface (26,
27), lymphocytes respond to a similar stimulus in a completely
different manner. In fact, in vitro studies show that binding of
CD81, in ways that mimic the interaction with HCV-E2, can in-
duce Ag-independent proliferation of  T cells (28) or naive B
cells (29) and act as a costimulus lowering the threshold for TCR-
mediated activation of  T cells (30, 31). Intriguingly, HCV-
infected individuals display symptoms that reflect extensive local-
ized lymphocyte proliferation such as viremia-dependent
perihepatic lymphadenopathy (32) and liver infiltration of a large
number of activated non HCV-specific T cells (33, 34).
In addition, various microenvironmental factors favor activation
of circulating lymphocytes in the liver. In particular, ligands for
the costimulatory molecule CD28 such as CD80 have been found
to be up-regulated on the surface of resident APCs and parenchy-
mal cells during HCV infection and to be related to exacerbated
disease conditions (35–37).
In this study, we show a novel TCR-independent activation
pathway for human T cells based on co-engagement (TCO cells) of
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the costimulatory molecule CD28 and a number of tetraspanins
including the HCV receptor CD81. These naive CD4 and CD8
T cells primed in vitro through ligation of CD28 and CD81 (TCO
cells) differentiate into memory or effector cells that are largely
unable to produce IFN-, but secrete considerable quantities of
type 2 and proinflammatory cytokines. In naive CD4 T cells, this
pattern of cytokine production is observed already at the level of
priming and is accompanied by early signaling through STAT6
and up-regulation of the Th2 master-control gene GATA-3 (38).
Based on the presence of high levels of ligands for CD28 in he-
patic lymphoid tissues and in the liver microenvironment, and the
concomitant appearance in situ of the only known direct ligand for
CD81 during HCV infection, we propose that TCO cells might be




Abs specific for IFN- were purchased from R&D Systems. Abs specific
for CD9, CD82, LFA-1, CD49d, CD2, HLA-A, HLA-B, and HLA-C, IL-4,
IL-12, IL-13 (clones M-L13, 50F11, HI111, 9F10, RPA-2.10, G46-2.6,
MP425D2, C8.6, JES10-5A2, all IgG1 isotype, respectively) were pur-
chased from BD Pharmingen. The anti-CD3 Ab (TR66) was provided by
A. Lanzavecchia (Institute for Research in Biomedicine, Bellinzona, Swit-
zerland). The Abs specific for CD81 and HCV-E2 (13, 29), recombinant
purified HCV-E2384–715 (39) and recombinant human IL-2 were reagents
developed and produced at Novartis Vaccines. The Ab specific for CD28
(clone ANC28.1/5D10) was purchased from Ancell. Nonspecific mouse
FIGURE 1. Coligation of CD81 and CD28 induces proliferation of naive T cells. A, Purified human CD45RO T cells were stimulated with plate-bound
anti-CD81 (CD81, clone 81N), anti-CD82 (CD82), anti-CD9 (CD9), or mouse IgG1 isotype control (mIgG1) all coated at 5 g/ml, or medium in the
presence of soluble Abs against CD28 (CD28, clone ANC28.1/5D10) (f), isotype-matched control (u) (all at 1 g/ml), or medium (). Data for controls
(right) show the response of the same cells to stimulation with plate-bound anti-CD3 or isotype control (CD3 (clone TR66), mIgG1 (control), both coated
at 1 g/ml) in the presence of soluble anti-CD28 (CD28 (clone ANC28.1/5D10), at 1 g/ml) or isotype control at the same concentration. B and C, The
same cells were cultured in triplicate for 72 h either with plate-bound anti-CD81 (5 g/ml) plus soluble anti-CD28 at varying concentrations (B) or in the
presence of the optimal concentration of soluble anti-CD28 (3 g/ml) plus solid phase anti-CD81 at different doses (C). After 72 h, cells were pulsed with
[3H]thymidine to measure their proliferation. Data represent the average cpm  SD from triplicate wells. One of three experiments with similar results is
shown.
FIGURE 2. Only engagement of CD81 by HCV-E2 or neutralizing Abs
synergizes with ligation of CD28. Human naive T cells were cultured with
recombinant HCV envelope proteins immobilized on plate-bound anti-E2
plus soluble anti-CD28 (clone ANC28.1/5D10). Additional controls in-
cluded cells cultured with anti-CD28 plus anti-CD81 either capable of
neutralizing binding of HCV-E2 (anti-CD81 (N81), 5 g/ml) or non-neu-
tralizing anti-CD81 (anti-CD81* (MG81), 5 g/ml), cells cultured with
anti-CD28 plus anti-E2 and recombinant HIV gp120 and cells cultured
with plate-bound anti-CD3 plus soluble anti-CD28. Proliferation was mea-
sured by [3H]thymidine incorporation. Data represent the average cpm 
SD measured from triplicate culture wells. One representative experiment
of three is shown.
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IgG1 isotype control was purchased from Sigma-Aldrich. Pacific blue,
FITC, PE, allophycocyanin, Alexa Fluor 488, Alexa Fluor 700 Abs specific
for CD3, CD4, CD8, CD25, CD45RO, CD45RA, L-selectin (CD62L),
CD69, CD154, phospho-STAT6, FoxP3, IFN-, IL-2, IL-4, IL-5, IL-10,
IL-13, TNF-, and equally labeled isotype-matched controls were pur-
chased from BD Pharmingen. The PE-conjugated Ab specific for human
CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2
cells) was purchased from Miltenyi Biotec. Recombinant human IL-4 and
IL-12 were purchased from R&D Systems and CFSE was purchased from
Molecular Probes. The inhibitors for Src kinases (PP2), p38, ERK, and
JNK MAPKs (inhibitor III, inhibitor II, and SP600125, respectively) were
all purchased from Calbiochem.
Cell purification
PBMC were purified from the blood of healthy adult individuals, after
having obtained informed consent, by Ficoll-Hypaque (GE-Healthcare) us-
ing gradient centrifugation. Naive T cells were purified by negative selec-
tion using the pan-T cell isolation kit (MACS; Miltenyi Biotec) plus anti-
CD45RO FITC (BD Pharmingen) Abs and anti-FITC microbeads
(Miltenyi Biotec). CD4 and CD8 naive T cells were purified by negative
selection adding anti-CD4 or anti-CD8 PE Abs (BD Pharmingen) plus
anti-PE microbeads (Miltenyi Biotec) to the reaction mix used for total
naive T cells. Cell purity was evaluated by flow cytometry and it was found
to be 97% for all the subsets purified.
Cell culture
All cultures were performed in RPMI 1640 medium (Life Technologies)
supplemented with penicillin, streptomycin, and glutamine (Life Tech-
nologies), 10% FCS (HyClone Laboratories) and kept at 37°C in a
humidified incubator. Naive T cells were cultured in duplicates at 2 
105 cells/well in 96-well flat-bottom plates (Costar). Anti-CD3 was pre-
viously immobilized at 1 g/ml in PBS on the surface of the plates by
incubating overnight at 4°C and, where indicated, was used together
with soluble anti-CD28 (clone ANC28.1/5D10, 1 g/ml). All other
Abs, unless otherwise stated, were immobilized at 5 g/ml. Recombi-
nant purified HCV-E2 was bound to solid phase anti-E2 by incubating
culture wells with a solution of protein in PBS for 1 h at 37°C. Coli-
gation of CD28 and CD81 was performed culturing cells on either plate-
bound anti-CD81 or HCV-E2 plus soluble anti-CD28 (clone ANC28.1/
5D10) at 3 g/ml, unless otherwise specified. Polyclonal nonpolarized
cell lines were generated by stimulation with plate-bound anti-CD3
(coated at 1 g/ml) plus soluble anti-CD28 (clone ANC28.1/5D10, 1
g/ml) for 4 days without additional cytokines followed by expansion
in medium containing only IL-2. Type 1 and type 2 polyclonal T cell
lines were prepared using the same stimulation but in the presence of
either IL-12 (5 ng/ml) plus anti-IL-4 and anti-IL-13 (5 g/ml) or IL-4
(200 U/ml) plus anti-IL-12 and anti-IFN- (5 g/ml) respectively, dur-
ing the initial 4 days of culture.
FIGURE 3. Expansion and differ-
entiation of human naive T cells fol-
lowing stimulation with anti-CD81
plus soluble anti-CD28. A, Purified
CD45RO T cells were labeled with
CFSE and cultured with the indicated
stimuli for 5 days. Cells were gated
for expression of CD4 and CD8 and
analyzed for cell division. One exper-
iment representative of two is shown.
B, Naive T cells were stimulated for 6
days as indicated. CD4 and CD8
cells were analyzed for surface levels
of CD45RA and CD45RO. C, CD4
and CD8 cells were analyzed for ex-
pression of CD62L at day 0 (gray line
histogram) and after 6 days of culture
(black line histogram). Cells stained
with isotype-matched controls (gray-
filled histogram) were also shown.
One representative experiment of
four is shown. D, Purified human na-
ive CD4 T cells were cultured for 3
days in the presence of the indicated
stimuli. Every 24 h cells were ana-
lyzed for expression of CD4 and
CD40L. Cells stained with isotype-
matched controls (gray-filled histo-
gram) are shown. One experiment
representative of four is shown.
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Duplicate cell cultures were pulsed at either 48 or 72 h with 0.5 Ci/well
[3H]thymidine (Amersham Biosciences), incubated for an additional 6 h at
37°C, and harvested onto filter plates (Packard Instruments). Cell counts
were analyzed using a TopCount NXT beta counter (Packard Instruments).
Inhibition assay
Naive human T cells were pretreated for 1 h with PP2, SP600125, p38
inhibitor III, and ERK inhibitor II at 37°C. Subsequently, cells were trans-
ferred to flat-bottom 96-well culture plates and stimulated in duplicate for
48 h. Then cell proliferation was measured by [3H]thymidine incorporation
and the percentage of inhibition of cell division was calculated using the
following formula: (1  (cpm of stimulated sample with inhibitor/cpm of
stimulated cells in medium))  100.
Flow cytometry
Cell labeling with CFSE was performed as described (40). After 5 days of
culture, cells were labeled using allophycocyanin-conjugated Abs, and
each assayed subpopulation consisted of 1 105 gated cells. Expression of
CD45RA, CD45RO, and CD62L was assayed on 1  104 gated CD4 and
CD8 T cells. CD40L/CD154 expression was assessed on highly purified
1  104 CD4 naive T cells at the indicated time points after stimulation.
CRTH2 expression was measured on 1  104 CD4 T cells after priming
in the indicated conditions and expansion in recombinant IL-2. Cell via-
bility was measured by propidium iodide incorporation. Intracellular de-
tection of cytokines was performed on cells stimulated with 200 nM PMA
and 1 g/ml ionomycin (Sigma-Aldrich) for 2 h. Brefeldin A (10 g/ml;
Sigma-Aldrich) was added for the last 4 h. Allophycocyanin anti-IFN-
and IL-10, PE anti-IL-4, IL-13, and IL–5, and FITC anti-IFN- (BD
Pharmingen) were used after fixation with 2% paraformaldehyde and per-
meabilization with 0.5% saponin (Sigma-Aldrich). Intracellular levels of
phospho-STAT6 were measured on 1  104 highly purified CD4 T cells
fixed in paraformaldehyde, permeabilized in methanol, and labeled with
Alexa Fluor 488 anti-phospho-STAT6 as described (41, 42). Intracellular
detection of FoxP3 was performed by first staining cells for surface ex-
pression of CD25. Then cells were fixed and permeabilized cells using the
FoxP3 buffer set (BD Pharmingen). Finally, cells were stained for FoxP3
expression. Samples were acquired on an LSR-II flow cytometer (BD Bio-
sciences) and data were processed using the software Flowjo (Tree Star).
Cytokine secretion assay
Supernatants were taken from cells cultured in duplicate that were stimu-
lated either for 24 h with anti-CD3 or with other stated combinations of
stimuli for the indicated time points. Supernatants were then assayed for
the presence of IFN-, IL-2, IL-4, IL-5, IL-10, and TNF- by the elec-
troluminescence multiplex system Sector 2400 Imager from Meso-Scale
Discovery. Data were imported and analyzed as for standard ELISA with
the Softmax Pro program (Molecular Devices). Total TGF- was measured
in the supernatant of anti-CD3-stimulated naive and in vitro-generated ef-
fector cells using the TGF-1 DuoSet ELISA development system (R&D
Systems). To minimize nonspecific background due to the high levels of
TGF- normally present in the FCS, cells were washed twice and cultured
in medium supplemented with 5% human serum (Sigma-Aldrich) for
restimulation.
Real-time PCR
Total RNA was extracted from purified CD4 T cells using the RNeasy kit
(Qiagen) according to the manufacturer’s instructions. Total RNA was
FIGURE 4. Differentiation poten-
tial of naive CD4 and CD8 T cells
following co-engagement of CD81
and CD28. Purified naive CD4 and
CD8 T cells were stimulated for
96 h as TCO cells under the indicated
conditions. E2 plus anti-E2 (E2 
anti-E2) represents HCV envelope pro-
tein E2 immobilized on plate-bound
anti-E2. Differentiation controls con-
sisted of naive cells stimulated for
96 h with solid phase anti-CD3 plus
soluble anti-CD28 in type 2 (Th2/
Tc2), type 1 (Th1/Tc1), or nonpolar-
izing conditions. All of the cultures
were expanded in IL-2, then cells
were restimulated with PMA plus
ionomycin for 2 h followed by an ad-
ditional 4 h in the presence of brefel-
din A for intracellular cytokine detec-
tion. A, CD4 T cells stained for IL-4
and IFN- (top row) and for IL-13
and IFN- (bottom row). Values
shown (top right) represent the per-
centage of cells present in each quad-
rant. One experiment representative
of five with similar results is shown.
B, CD8 naive T cells stained for
IL-4 plus IL-13 in the same fluores-
cence channel and IFN-. Cytokine
production levels are shown for each
quadrant. One experiment representa-
tive of three with similar results is
shown. C, Expression of CRTH-2 by
cells as in A after expansion in IL-2
(black line). Control cells stained
with isotype matched control (gray
filled histograms) are shown. One ex-
periment representative of five is
shown.
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cleaned from DNA using DNase I Amplification Grade and retrotrans-
cribed using Thermo Script RT-PCR System (Invitrogen) with oligo(dT) as
primers. PCR was prepared using the iQ SYBR Green Supermix (Bio-Rad)
in which ROX reference dye (Stratagene), cDNA template, and the fol-
lowing primer pairs were added: T-bet, 5-ACTGGAGGTGTCGGGGA
AAC-3, 5-GCCACAGTAAATGACAGGAATG-3; GATA-3, 5-CCCC
TTCTTCTCTTTGCTAAAC-3, 5-GTCGTTGAATGATTTGCTTTCG-
3; and GAPDH, 5-CGCCAGCCGAGCCACATC-3, 5-CGCCCAATA
CGACCAAATCCG-3. Samples were prepared in triplicate, run on a
MX3000 ThermoCycler and analyzed using the MX PRO software (Strat-
agene). GAPDH was used as a control housekeeping gene. Additional con-
trols consisted in samples without cDNA and derived from RNA not
treated with reverse transcriptase or with DNase I. Following PCR, the
melting curve for each product was determined. Finally, the correct size of
the PCR products was controlled by agarose gel electrophoresis. Mean
quantity of endogenous GAPDH was determined for each type of stimulus.
The relative expression ( SD) of GATA-3 and T-bet relative to GAPDH
was calculated by cycle threshold (Ct) for each type of stimulus using
CtGAPDH  CtGATA-3 (GATA-3) or CtGAPDH  CtT-bet (T-bet), respec-
tively. Subsequently, the ratio of GATA-3 to T-bet was calculated as
GATA-3  T-bet (Ct) for each type of stimulation. The ratio in
stimulated cells was normalized to the ratio of GATA-3 to T-bet at t 	 0.
Results
Human naive T cells proliferate when CD81 and CD28 are
simultaneously engaged on their surface
Based on previous observations indicating that during chronic hep-
atitis C a large portion of activated intrahepatic T lymphocytes are
not specific for HCV (17, 33, 34), we hypothesized that this might
be the consequence of an unknown form of virus-host interaction.
Thus, we decided to test whether co-engagement of the viral re-
ceptor CD81 and other non-Ag-specific surface molecules could
elicit some form of TCR-independent activation in resting T cells.
In our experimental system, we found that highly purified human
naive T cells proliferated vigorously when stimulated with an anti-
CD81 mAb in combination with anti-CD28 mAbs (Fig. 1A). How-
ever, this was not observed with Abs specific for other costimu-
latory molecules such as CD2, LFA-1, and CD49d, which were
administered across a wide concentration range (from 0.1 to 10
g/ml, data not shown). As tetraspanins are thought to be involved
in cis-acting interactions among different members of the same
family (6), we tested whether we could induce cell proliferation by
engaging CD28 concomitantly with other tetraspanins such as
CD82 and CD9 (Fig. 1A). It was found that also co-engagement of
CD82 with CD28 triggered robust proliferation of naive T cells,
whereas ligation of CD28 with CD9 resulted in moderate cell
proliferation.
When we further analyzed the contribution of each of the two
stimuli, we found that the magnitude of the cell response was
directly proportional to the extent of binding of either CD28 (Fig.
1B) or the tetraspanin CD81 (Fig. 1C). However, using anti-CD28
mAbs at concentrations higher than 3 g/ml consistently caused
proliferation to fall below maximal levels.
Only HCV-like binding of CD81 synergizes with ligation of
CD28
Among the tested tetraspanins that elicited strong proliferation,
only CD81 has a clearly identified counter-receptor, and that is the
HCV envelope protein E2 (13). Coherently with our previous re-
sults, we found that engagement of CD81 by immobilized HCV
envelope protein was as efficient as anti-CD81 mAbs in inducing
cell division when coupled to soluble anti-CD28 (Fig. 2). Accord-
ingly, only anti-CD81 mAbs that neutralize binding of the HCV
FIGURE 5. Cytokine profile of activated
CD4 TCO effector cells. A, Purified naive
CD4 T cells were stimulated for 96 h under
specific conditions. TCO cells were stimulated
by HCV-E2 immobilized on plate-bound anti-
E2 plus soluble anti-CD28 (E2  E2 
CD28) or on plate-bound anti-CD81 plus sol-
uble anti-CD28 (CD81  CD28). Differenti-
ation controls were stimulated by plate-bound
anti-CD3 plus soluble anti-CD28 in either type 2
(Th2) or type 1 (Th1) conditions. Additional
controls were stimulated by solid phase anti-
CD3 plus soluble anti-CD28 (CD3  CD28)
or plate-bound anti-CD81 (CD3  CD81).
All of the cultures were expanded in IL-2 and
restimulated in duplicate with plate-bound anti-
CD3 for 24 h. Culture supernatants were taken
and assayed for the presence of multiple cyto-
kines indicated (top) by electrochemilumines-
cence detection using a Meso-Scale 2400 Imager.
Data represent the average concentration SD of
the tested cytokine, expressed in picograms per
milliliter less the background measured for cells
stimulated with mouse IgG1 isotype control. One
experiment representative of three is shown.
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envelope protein E2 to CD81 (29) could be used to induce prolif-
eration of naive T cells. In both cases, the amount of cell activation
detected was comparable to that of naive T cells treated with stan-
dard stimuli such as anti-CD3 plus anti-CD28.
Both CD4 and CD8 naive T cells are activated by binding
of CD81 and CD28 and mature into effector or memory cells
Using the CFSE dilution assay, it was ascertained that both CD4
and CD8 naive T cells underwent proliferation when stimulated
with anti-CD81 and anti-CD28 (Fig. 3A). The number of cell di-
visions accomplished during 5 days, as well as the magnitude of
the population of cells undergoing mitosis, was very similar to
what was observed for controls stimulated with anti-CD3 plus anti-
CD28. Proliferation of cells stimulated with anti-CD81 plus anti-
CD28 was accompanied by down-regulation of surface markers
such as CD45RA and CD62L and up-regulation of CD45RO (Fig.
3, B and C), suggesting that these cells were induced to differen-
tiate into effector/memory cells (43). In addition, they also ex-
pressed CD40L (Fig. 3D), a surface receptor through which T cells
exert their helper function onto B cells (44). Expression of this
marker peaked after 48 h for cells stimulated with anti-CD81 plus
anti-CD28 and at 24 h for cells treated with anti-CD3 plus anti-
CD28, subsequently decreasing to similar levels after 72 h. For
easier description in this study, we will refer to the effector cells
generated by simultaneous binding of CD81 and CD28 as TCO
cells, as they arise upon engagement of costimulatory
molecules only.
Co-engagement of CD81 and CD28 induces differentiation of
naive CD4 and CD8 T lymphocytes into type 2 effector cells
To evaluate the differentiation potential of naive T cells primed by
binding of CD81 and CD28, we compared these with polyclonal
type 2, type 1, and nonpolarized T cell lines. After expansion in
IL-2, cells were restimulated with PMA and ionomycin and as-
sayed for intracellular levels of effector cytokines (Fig. 4). Pro-
duction of IFN- could not be detected in CD4 T cells primed
with either HCV envelope proteins or anti-CD81 Abs plus anti-
CD28. In contrast, these cells displayed levels of type 2 cytokines
such as IL-4 and IL-13 (45), which closely resembled what was
observed for cells primed under Th2 conditions (Fig. 4A). Also
CD8 naive T cells stimulated with HCV-E2 or anti-CD81 plus
anti-CD28 were able to produce IL-4, IL-13, and IFN- in com-
parable amounts to what was made by type 2 Tc cell (Tc2) controls
(Fig. 4B). These cells were also capable of making IL-5; however,
in lower amounts than the in vitro generated Tc2 cells (our un-
published data). A similar effect was also observed on both CD4
and CD8 cells primed by ligation of CD82 and CD28. However,
when effector cells were generated by co-engagement of CD3 plus
CD81 and CD28, they extensively proliferated (our unpublished
data), but did not differentiate into type 2 cells. Rather, they re-
sembled nonpolarized cells. In line with these results, only CD4
TCO and Th2 cells expressed chemoattractant receptor homologous
molecule expressed on Th2 (CRTH2) (Fig. 4C), a marker for ter-
minally differentiated type 2 cells (46, 47).
CD4 TCO cells are type 2-polarized effector cells with strong
proinflammatory potential
To analyze more thoroughly the cytokine profile of CD4 TCO
effector cells, we compared these with in vitro-generated Th1 and
Th2 cells using a system able to detect secretion of up to seven
cytokines, after 24 h of TCR-mediated stimulation (Fig. 5). These
experiments confirmed that CD4 TCO cells do not produce
IFN-, but rather Th2 cytokines such as IL-4, IL-13, IL-5, and the
potent cross-regulator of type 1 immunity, IL-10 (48). In most
cases the levels of IL-4, IL-13, IL-5, and IL-10 were comparable
if not superior to those observed for Th2 effector cells. In addition,
TCO cells appeared to be strong producers of the proinflammatory
FIGURE 6. FoxP3 expression kinetics
during TCO cell differentiation and TGF-
production capacity by CD4 TCO effector
cells. A, Purified naive CD4 T cells were
cultured in duplicates and stimulated as in-
dicated. At the given time points, cells were
stained for surface expression of CD25 and
intracellular detection of FoxP3 by flow cy-
tometry. Values shown (top left) represent
the percentage of cells present in each quad-
rant. One experiment representative of three
is shown. B, The same cells from A were
stimulated with plate-bound anti-CD3 for
24 h either when freshly purified (bottom) or
after 6 days of culture followed by expan-
sion in IL-2 (top). Culture supernatants were
collected and assayed for the presence of to-
tal TGF-1 by ELISA. One experiment rep-
resentative of three is shown. TCO cells rep-
resent plate-bound anti-CD81 (clone 81N)
plus soluble anti-CD28 (clone ANC28.1/
5D10); CD3 plus CD28 represents solid
phase anti-CD3 (clone TR66) plus soluble
anti-CD28; and mIgG1 represents mouse
IgG1 isotype control.
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cytokine TNF- (49) and the T cell growth factor IL-2 (50), dis-
tinguishing them from Th2 controls, where these two cytokines
were detected in minimal amounts. To ascertain whether one of the
two molecules predominantly contributed to the polarization of
TCO cells, we included controls in which cells were primed in vitro
by binding of the TCR and costimulated through either CD81 or
CD28. In both cases, the effector cells obtained behaved like cells
cultured in nonpolarizing conditions, suggesting that, as costimuli,
these molecules were inadequate to push naive T cells to become
Th2 cells. Thus, only by simultaneous binding of CD81 and CD28,
in the absence of TCR stimulation, were we able to induce CD4
naive T cells to differentiate into effector cells capable of produc-
ing large quantities of Th2 and proinflammatory cytokines.
The high amount of IL-10 secreted by CD4 TCO cells is rem-
iniscent of the effector phenotype of CD4 regulatory T cells.
Thus we decided to test whether TCO cells also expressed the reg-
ulatory T cell master control gene FoxP3 (51). We found that this
transcription factor was similarly expressed by naive CD4 T cells
primed by either triggering of the TCR or by co-engagement of
CD28 and CD81 (Fig. 6A). In addition, when tested for the capac-
ity to secrete other T cell inhibitory cytokines such as TGF- (52),
CD4 TCO cells behaved as CD4 effector cells generated by
ligation of the TCR (53, 54). Therefore, we conclude that naive
CD4 cells stimulated through CD81 and CD28 do not preferen-
tially differentiate into regulatory T cells.
CD8 TCO cells show a type 2-biased cytokine profile
To further analyze CD8 TCO cells we focused on whether they
secreted large amounts of TNF- or IL-10, thus exerting either an
enhanced proinflammatory or T cell inhibitory activity. In contrast
FIGURE 7. Proinflammatory and cross-regulatory potential of activated CD8 TCO effector cells. A, Purified naive CD8 T cells were primed with
HCV-E2 or anti-CD81 plus anti-CD28 for 96 h under the same conditions as indicated in Fig. 5. All of the cultures were expanded in IL-2 and restimulated
in duplicate with plate-bound anti-CD3 for 24 h. Culture supernatants were taken and assayed by electrochemiluminescence for the presence of the
cytokines TNF- and IL-10 indicated (top) and detected using a Meso-Scale 2400 Imager. Data represent the average concentration  SD of the tested
cytokine, expressed in picograms per milliliter less background measured for cells stimulated with mouse IgG1 isotype control. One experiment repre-
sentative of three is shown. B, The same cells from A were restimulated with PMA and ionomycin for 2 h followed by an additional 4 h in the presence
of brefeldin A for intracellular detection of IFN- and IL-10. Values shown (top right) represent the percentage of cells present in each quadrant. One
experiment representative of three is shown.
FIGURE 8. Intracellular signaling requirements for priming of TCO cells. Naive human T cells were purified from healthy adult donors and pretreated
for 1 h at 37°C with inhibitors specific for Src kinases, p38, ERK, and JNK MAPKs at the indicated concentrations. Then cells were cultured in duplicate
under stimulation with either plate-bound anti-CD3 plus soluble anti-CD28 (F) or plate-bound anti-CD81 plus soluble anti-CD28 (E) for 48 h at 37°C.
Additional controls consisted of cells preincubated with medium only (M) or in the presence of DMSO (D) at the same concentration used at the highest
dose of inhibitor. Cell proliferation was measured by [3H]thymidine incorporation and data points represent the mean inhibition observed. One experiment
representative of five with similar results is shown.
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to CD4 TCO cells, the quantity of IL-10 and TNF- released in
the culture medium by their CD8 TCO counterparts and by con-
ventionally activated CD8 cells was similar (Fig. 7A). A further
difference between CD4 and CD8 TCO cells was that the latter
included a minor subpopulation still capable of producing IFN-
(Fig. 4B). Thus we tested whether this subset also secreted IL-10.
We found that some Tc1 and Tc0 cells were capable of producing
both IFN- and IL-10, whereas IL-10 was made only by some TCO
cells within the larger subpopulation of IFN--negative cells (Fig.
7B). Overall, these data indicate that the type 2 bias of CD8 T
cells is similar to that of CD4 T cells, but that the overall cyto-
kine profile is not identical.
CD4 TCO effector cells do not develop from Th0 precursors
The striking capabilities of TCO cells led us to investigate how they
might arise. First we tested whether the stimuli underlying their
activation triggered similar or divergent signaling pathways when
compared with engagement of the CD3-TCR complex. We found
that both types of stimulation were similarly susceptible to inhib-
itors of Src kinases, p38 and ERK (Fig. 8). However, specific
inhibition of the MAPK JNK completely blocked CD81 plus
CD28-dependent activation of naive T cells but only partially the
stimulation through the TCR.
Because JNK is thought to be important for activation of effector
and not naive precursors (55), we decided to ascertain whether
TCO cells followed a sequential development pathway involving a
Th0 precursor capable of producing both IFN- and IL-4 (38, 56,
57) or differentiated directly into type 2 effector cells.
During a time course experiment ranging from 6 to 72 h post-
activation, we found that freshly isolated naive CD4 T cells
primed in vitro by coligation of CD81 and CD28 secreted IL-4
much earlier than IFN-, whereas the onset of production of both
cytokines coincided for cells stimulated through the TCR. In ad-
dition, IFN- production by TCO cells was almost 30 times lower
than by nonpolarized controls, whereas IL-4 was consistently de-
tected in superior amounts, suggesting a direct Th2-like polariza-
tion. This primacy was observed also for other type 2 cytokines
such as IL-5 and IL-13, and for TNF- and IL-2. Only IL-10 was
higher in the supernatants taken from cells stimulated on the TCR
(Fig. 9A). These differences were not due to different degrees of
activation because TCO and nonpolarized controls expressed
equivalent levels of the activation markers CD69 and CD25 at all
time points (our unpublished data).
Stimulated cells were also assayed by flow cytometry for intra-
cellular levels of the phosphorylated or active form of STAT6 (Fig.
9B). This transcription factor becomes activated upon binding of
IL-4 to its own receptor and is considered to be essential for ex-
pression of the Th2 master control gene GATA-3 and for sustained
production of type 2 cytokines (38). Activated STAT6 could be
detected in TCO-primed cells as early as 24 h and its levels increased
with time. Phosphorylation of this protein could be inhibited by
neutralizing Abs against IL-4, and no difference in the levels of active
STAT6 was observed between TCO cells primed either in the presence
or absence of exogenous IL-4. Accordingly, as its expression is
thought to be dependent on STAT6 signaling, GATA-3 mRNA was
FIGURE 9. Early cytokine produc-
tion and STAT6 phosphorylation in na-
ive T cells under TCO priming. A, Pu-
rified naive CD4 T cells were cultured
in duplicate and stimulated as indicated
by each symbol and described in Fig.
1A. At the given time points, culture su-
pernatants were collected and assayed
for the presence of multiple cytokines
by electrochemiluminescence using a
Meso-Scale 2400 imager. Data points
represent the average concentration 
SD of the tested cytokine (in picograms
per milliliter). One experiment repre-
sentative of three is shown. B, At the
indicated time points, the same cells
from A were stained for intracellular
detection of phosphorylated STAT6 by
flow cytometry. Levels of phospho-
STAT6 (thick line histogram) in cells
cultured either under TCO stimulation
(top) or with anti-CD3 plus soluble anti-
CD28 (bottom). Cells stimulated in the
same conditions but in the presence of
neutralizing anti-IL-4 (thin line histo-
gram) are indicated. Cells treated with
the same stimuli plus 400 U/ml exoge-
nous IL-4 (gray line histogram) and Al-
exa Fluor 488-conjugated isotype con-
trols (gray-filled histogram) are also
shown. One experiment representative
of three, relative to the same cells in A,
is shown. TCO represents plate-bound
anti-CD81(clone81N)plussolubleanti-
CD28 (clone ANC28.1/5D10) and
CD3 plus CD28 represents solid
phase anti-CD3 (clone TR66) plus sol-
uble anti-CD28.
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found to be up-regulated in TCO cells after 3 days of culture, whereas
expression of the Th1 promoting gene T-bet was reduced (Fig. 10).
Discussion
Our results presented in this study show a new TCR-independent
pathway of activation for human naive T cells based on simulta-
neous engagement of the two costimulatory molecules CD81 and
CD28. Whereas other forms of TCR-independent activation of na-
ive T cells have been observed before (58–62), CD81 and CD28
were never described as functional partners. In other systems,
binding of CD81 is sufficient to induce proliferation of  T cells
(28) and naive B lymphocytes in vitro (29). However, our previous
(30) and present data indicate that in the case of  T cells, the
sole engagement of CD81 does not exert similar effects. Binding of
CD81 either with mAbs or recombinant HCV envelope proteins, or
of CD82 with mAbs, synergized with concomitant engagement of
CD28 and not with other markers such as CD2, LFA-1, and
CD49d.
As tetraspanins are involved in lateral interactions among them-
selves and other nontetraspanin proteins (6), it is possible that
CD82 and CD9 participate in the signaling complex that we in-
duced by the engagement of CD81 and vice versa. In line with
previous studies showing similar costimulatory ability for these
three tetraspanins (63, 64), we show that binding of either of these
three molecules on T cells leads to a similar biological response
(30, 36, 37). However, the magnitude of the response elicited by
engagement of CD9 was far inferior to what was observed for
engagement of CD82 or CD81.
Our further characterization showed that both CD4 and CD8
naive cells proliferated in response to co-engagement of CD81 and
CD28, and they did so as robustly as cells stimulated through the
TCR. Eventually these cells differentiated into effector or memory
T cells that produced predominantly type 2 cytokines such as IL-4,
IL-13, IL-5 (65), and the potent cross-regulator of type 1 immunity
IL-10 (48, 66), whereas the levels of IFN- detected from CD4
and CD8 TCO cells were low and comparable with levels ob-
served for type 2 cells generated in vitro by strongly polarizing
conditions (46). Furthermore, CD4 TCO effector cells expressed
CRTH2 (47), a marker characteristic for terminally differentiated
type 2 cells that retain their differentiated state even if cultured
under type 1 conditions in vitro (46). Given the high amounts of
IL-10 secreted by CD4 TCO cells, we tested whether this re-
sponse was associated with increased levels of expression of the
regulatory T cell master control gene FoxP3 (51), and whether
other T cell inhibitory cytokines such as TGF- were also pro-
duced (52). In either case we could not observe any preferential
induction by the coligation of CD28 and CD81, indicating that this
stimulation does not exert a bias toward regulatory T cell devel-
opment. Also CD8 TCO cells secrete IL-10. However, this pro-
duction was always inferior to that observed for Tc1 and Tc2 con-
trols. Overall, our data supports the hypothesis that the production
of IL-10 by CD4 TCO cells is a consequence of their strong type
2 polarization (48), whereas in the case of CD8 TCO cells, this
property seems to be broadly shared among different types of
CD8 effector T cells.
The striking differentiation of both CD4 and CD8 TCO cells
into type 2 effectors is based on the synergistic involvement of two
molecules, CD81 and CD28, both described in several studies as
endowed with type 2 immunity-promoting activity (11, 67, 68).
Our observation that the new process of activation described in this
study was dependent on active Src kinases hints at a molecular
mechanism for the proximal signaling events involved in the pro-
cess. Because binding of the TCR, CD81, or CD28 can induce
activation of the membrane proximal Src kinase p56lck in T cells
(31, 69), co-engagement of CD81 and CD28 might result in the
recruitment of substrate-harboring lipid rafts (70) or tetraspanin-
enriched microdomains (6) around foci of active lck, triggering
sufficient amounts of signals that would finally lead to cell
division.
When we further characterized the process of generating TCO
cells, we found at priming that the onset of IL-4 secretion preceded
the onset of IFN- secretion, which remained very low throughout
the experiment. This caused strong early IL-4-dependent signaling
through STAT6, eventually leading to up-regulation of the Th2
master control gene and regulator of IL-10 transcription GATA-3
and down-regulation of the Th1 counterpart T-bet (38, 71, 72).
These data suggest that TCO cells might differentiate directly into
Th2-like cells skipping an initial “Th0” stage, characterized by
dual secretion of IL-4 and IFN- (46, 56, 57). The hypothesis of an
“accelerated” program of differentiation in TCO cells is consistent
with the observation that inhibition of the MAPK JNK completely
blocks CD81 plus CD28-dependent activation of naive T cells but
only partially the stimulation through the TCR. In fact, JNK can be
activated by sole binding of CD81 in B cells (29) and is thought to
be required for the activation of effector and not naive T cells (55).
Apart from proposed homotypic interactions, there are no
known physiologic ligands for CD81 and CD82 (6). Thus, it is
difficult to envisage that an activation process as described in this
study occurs in healthy individuals in vivo. However, because the
HCV envelope protein E2 is a ligand for CD81 (13), we propose that
the CD81-CD28 synergistic engagement may be productive during
HCV infection. Accordingly, we show that only those regions of
CD81 recognized by the virus can mediate T cell priming when co-
engaged with CD28. The natural ligands for the latter, namely CD80
and CD86, are largely expressed in secondary lymphoid organs
(73) and under certain conditions in the liver (35–37). However,
whereas HCV proteins like the core Ag can be easily detected in
the bloodstream (74), this is not the case for E2, which has been
detected only at liver biopsy (75, 76). Thus, it seems that the li-
gands required for activation to occur, namely CD80, CD86, and
HCV-E2, are present in sufficient amounts only in the liver and,
possibly, its draining secondary lymphoid organs. Interestingly,
lymphadenopathy of perihepatic lymph nodes is commonly de-
tected in HCV-infected individuals (32, 77, 78). This symptom is
considered to be highly predictive of HCV infection when detected
by chance (77, 78), and its magnitude directly correlates with the
FIGURE 10. Modulation of master transcription factors in CD4 TCO
cells. Purified naive CD4 T cells were harvested at t	 0 (t0) or after 72 h
of culture under TCO, Th2, Th1, and nonpolarizing conditions. RNA was
extracted and analyzed for expression of T-bet, GATA-3, and GAPDH
using real-time fluorogenic PCR. Each reaction was performed in triplicate.
For each stimulus, GATA-3 and T-bet transcripts were normalized to
GAPDH. The ratio between the normalized level of GATA-3 over T-bet
was calculated. The ratio was normalized by dividing it with the ratio
GATA-3 over T-bet for nonstimulated cells. Results represent the aver-
age  SD of GATA-3 over T-bet ratio. One experiment representative of
three with similar results is shown.
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level of viremia, increased frequency of peripheral CD4 and
CD8 T cells, and progression of liver fibrosis (32), a condition
promoted by type 2 cytokines (79–81). We suggest that TCO cells
may participate in the enlargement of liver-associated lymph
nodes, from which they would affect the quality of the HCV-spe-
cific immune response.
Alternatively, TCO cells could be generated directly in the in-
fected liver, when recirculating naive T cells interact with acti-
vated CD80 Kupffer cells in the narrow and slow flowing hepatic
sinusoidal vasculature. Accordingly, formation of clusters of acti-
vated Kupffer cells and T cells have been observed in the blood
vessels, the transendothelial interphase, and within the paren-
chyma of liver specimens from HCV-infected individuals (36). In
these patients, CD80 expression was also found on the surface of
hepatocytes (35, 37). Because also these cells have been shown to
contact extensively with circulating lymphocytes through the un-
derlying fenestrated liver sinusoidal endothelial cells (82), it is thus
conceivable that upon HCV infection, TCO-like activation of naive
T cells could occur intrahepatically.
We propose that TCO cells generated in vivo would oppose the
generation of a strong type 1-specific response, which has been
shown to prevent the establishment of chronic HCV infection and
lead to virus elimination (18–20, 83). In fact, nonresolving pa-
tients display phases of HCV-specific type 2 responses coinciding
with low to undetectable intrahepatic T cell-mediated cytotoxicity
(22, 23). Even during strong cytolytic responses, HCV-specific
type 1 T cells in the periphery have intrahepatic counterparts that
produce type 2 cytokines (22). Similarly, bulk-stimulated intrahe-
patic CD4 and CD8 T cells from chronic patients produce less
IFN- than peripheral blood cells and, in the case of CD8 cells,
lower levels of perforin (21), resembling Tc2 lymphocytes (84,
85). These data hint at the presence of an elusive type 2 biasing
factor in the HCV-infected liver or associated lymphoid tissues,
and we suggest that this might include nonspecific effector TCO
cells capable of exerting type 2 pressure on HCV-specific cells.
During priming in vitro, TCR engagement prevents type 2 polar-
ization of T cells costimulated on CD81 and CD28. It is therefore
conceivable that, in infected individuals, Ag-specific cells cannot
be directly skewed away from type 1 immunity, but rather undergo
modulation by the cytokines secreted by TCO cells in the surround-
ing microenvironment (46, 86, 87).
TCO cells might also participate in the ongoing inflammation
that characterizes the HCV-infected liver. In fact, CD4 TCO cells
are distinct from canonical Th2 cells as they secrete the proinflam-
matory mediator TNF- and, in line with their strong proliferation
potential, large amounts of IL-2. As for CD8 cells, CD81 and
CD28 stimulation does not preferentially induce TNF- in com-
parison to conventional activation, as was observed in CD4 T
cells. However, CD8 T cells are overall strong producers of
TNF- and therefore have a high proinflammatory potential. In-
terestingly, CD28CD8 effector T cells have been detected in the
liver, and their relative frequency directly correlates with higher
scores of inflammation (21), a condition favored by local secretion
of TNF- (49, 88, 89). In addition, recent works also correlate
strong expression of E2 on the membrane of hepatocytes with
higher inflammation of the liver (75).
Overall, this study demonstrates that naive human T cells can be
primed to become type 2-like proinflammatory effector cells via a
novel pathway mediated by co-engagement of two costimulatory
molecules, the first being CD28 and the second a member of the
tetraspanin family of proteins such as CD81, CD82, or CD9. The
liver and draining lymph nodes of HCV-infected humans are en-
riched in ligands for both CD28 and CD81 and therefore represent
an environment in which this phenomenon is likely to occur. Our
data delineates a putative mechanism of immune escape by which
the HCV counteracts specific type 1 responses associated with vi-
ral clearance.
Acknowledgments
We thank Flora Castellino, Grazia Galli, Andrew Edwards, Angela Nobbs,
Kate Seib, and Robert Janulczyk for critical reading of the manuscript.
Disclosures
All authors are or were employees of Novartis Vaccines, which funded this
study.
References
1. van der Merwe, P. A., and S. J. Davis. 2003. Molecular interactions mediating T
cell antigen recognition. Annu. Rev. Immunol. 21: 659–684.
2. Acuto, O., and F. Michel. 2003. CD28-mediated co-stimulation: a quantitative
support for TCR signalling. Nat. Rev. Immunol. 3: 939–951.
3. Udagawa, T., D. G. Woodside, and B. W. McIntyre. 1996. 41 (CD49d/CD29)
integrin costimulation of human T cells enhances transcription factor and cyto-
kine induction in the absence of altered sensitivity to anti-CD3 stimulation. J. Im-
munol. 157: 1965–1972.
4. Wakkach, A., F. Cottrez, and H. Groux. 2001. Differentiation of regulatory T
cells 1 is induced by CD2 costimulation. J. Immunol. 167: 3107–3113.
5. Van Seventer, G. A., Y. Shimizu, K. J. Horgan, and S. Shaw. 1990. The LFA-1
ligand ICAM-1 provides an important costimulatory signal for T cell receptor-
mediated activation of resting T cells. J. Immunol. 144: 4579–4586.
6. Levy, S., and T. Shoham. 2005. The tetraspanin web modulates immune-signal-
ling complexes. Nat. Rev. Immunol. 5: 136–148.
7. Cherukuri, A., R. H. Carter, S. Brooks, W. Bornmann, R. Finn, C. S. Dowd, and
S. K. Pierce. 2004. B cell signaling is regulated by induced palmitoylation of
CD81. J. Biol. Chem. 279: 31973–31982.
8. Mittelbrunn, M., M. Yanez, D. Sancho, A. Ursa, and F. Sanchez-Madrid. 2002.
Cutting edge: dynamic redistribution of tetraspanin CD81 at the central zone of
the immune synapse in both T lymphocytes and APC. J. Immunol. 169:
6691–6695.
9. Cherukuri, A., T. Shoham, H. W. Sohn, S. Levy, S. Brooks, R. Carter, and
S. K. Pierce. 2004. The tetraspanin CD81 is necessary for partitioning of coli-
gated CD19/CD21-B cell antigen receptor complexes into signaling-active lipid
rafts. J. Immunol. 172: 370–380.
10. Maecker, H. T. 2003. Human CD81 directly enhances Th1 and Th2 cell activa-
tion, but preferentially induces proliferation of Th2 cells upon long-term stimu-
lation. BMC Immunol. 4: 1.
11. Deng, J., R. H. Dekruyff, G. J. Freeman, D. T. Umetsu, and S. Levy. 2002.
Critical role of CD81 in cognate T-B cell interactions leading to Th2 responses.
Int. Immunol. 14: 513–523.
12. Maecker, H. T., M. S. Do, and S. Levy. 1998. CD81 on B cells promotes inter-
leukin 4 secretion and antibody production during T helper type 2 immune re-
sponses. Proc. Natl. Acad. Sci. USA 95: 2458–2462.
13. Pileri, P., Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, R. Petracca,
A. J. Weiner, M. Houghton, D. Rosa, G. Grandi, and S. Abrignani. 1998. Binding
of hepatitis C virus to CD81. Science 282: 938–941.
14. Houghton, M., and S. Abrignani. 2005. Prospects for a vaccine against the hep-
atitis C virus. Nature 436: 961–966.
15. Feld, J. J., and J. H. Hoofnagle. 2005. Mechanism of action of interferon and
ribavirin in treatment of hepatitis C. Nature 436: 967–972.
16. Dustin, L. B., and C. M. Rice. 2006. Flying under the radar: the immunobiology
of hepatitis C. Annu. Rev. Immunol. 25: 71–99.
17. Bowen, D. G., and C. M. Walker. 2005. Adaptive immune responses in acute and
chronic hepatitis C virus infection. Nature 436: 946–952.
18. Thimme, R., D. Oldach, K. M. Chang, C. Steiger, S. C. Ray, and F. V. Chisari.
2001. Determinants of viral clearance and persistence during acute hepatitis C
virus infection. J. Exp. Med. 194: 1395–1406.
19. Wedemeyer, H., X. S. He, M. Nascimbeni, A. R. Davis, H. B. Greenberg,
J. H. Hoofnagle, T. J. Liang, H. Alter, and B. Rehermann. 2002. Impaired effector
function of hepatitis C virus-specific CD8 T cells in chronic hepatitis C virus
infection. J. Immunol. 169: 3447–3458.
20. Gruener, N. H., F. Lechner, M. C. Jung, H. Diepolder, T. Gerlach, G. Lauer,
B. Walker, J. Sullivan, R. Phillips, G. R. Pape, and P. Klenerman. 2001. Sus-
tained dysfunction of antiviral CD8 T lymphocytes after infection with hepatitis
C virus. J. Virol. 75: 5550–5558.
21. Wang, J., T. H. Holmes, L. L. de Guevara, R. Cheung, T. L. Wright, X. S. He,
and H. B. Greenberg. 2006. Phenotypic and functional status of intrahepatic T
cells in chronic hepatitis C. J. Infect. Dis. 194: 1068–1077.
22. Prezzi, C., M. A. Casciaro, V. Francavilla, E. Schiaffella, L. Finocchi,
L. V. Chircu, G. Bruno, A. Sette, S. Abrignani, and V. Barnaba. 2001. Virus-
specific CD8 T cells with type 1 or type 2 cytokine profile are related to different
disease activity in chronic hepatitis C virus infection. Eur. J. Immunol. 31:
894–906.
23. Tsai, S. L., Y. F. Liaw, M. H. Chen, C. Y. Huang, and G. C. Kuo. 1997. Detection
of type 2-like T-helper cells in hepatitis C virus infection: implications for hep-
atitis C virus chronicity. Hepatology 25: 449–458.
24. Dumoulin, F. L., A. Bach, L. Leifeld, M. El-Bakri, H. P. Fischer, T. Sauerbruch,
and U. Spengler. 1997. Semiquantitative analysis of intrahepatic cytokine
mRNAs in chronic hepatitis C. J. Infect. Dis. 175: 681–685.
183The Journal of Immunology
 at U












25. Fan, X. G., W. E. Liu, C. Z. Li, Z. C. Wang, L. X. Luo, D. M. Tan, G. L. Hu,
and Z. Zhang. 1998. Circulating Th1 and Th2 cytokines in patients with hepatitis
C virus infection. Mediators Inflamm. 7: 295–297.
26. Crotta, S., A. Stilla, A. Wack, A. D’Andrea, S. Nuti, U. D’Oro, M. Mosca,
F. Filliponi, R. M. Brunetto, F. Bonino, et al. 2002. Inhibition of natural killer
cells through engagement of CD81 by the major hepatitis C virus envelope pro-
tein. J. Exp. Med. 195: 35–41.
27. Tseng, C. T., and G. R. Klimpel. 2002. Binding of the hepatitis C virus envelope
protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195: 43–49.
28. Tseng, C. T., E. Miskovsky, and G. R. Klimpel. 2001. Crosslinking CD81 results
in activation of TCR T cells. Cell Immunol. 207: 19–27.
29. Rosa, D., G. Saletti, E. De Gregorio, F. Zorat, C. Comar, U. D’Oro, S. Nuti,
M. Houghton, V. Barnaba, G. Pozzato, and S. Abrignani. 2005. Activation of
naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-
associated B lymphocyte disorders. Proc. Natl. Acad. Sci. USA 102:
18544–18549.
30. Wack, A., E. Soldaini, C. Tseng, S. Nuti, G. Klimpel, and S. Abrignani. 2001.
Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-
stimulatory signal for human T cells. Eur. J. Immunol. 31: 166–175.
31. Soldaini, E., A. Wack, U. D’Oro, S. Nuti, C. Ulivieri, C. T. Baldari, and
S. Abrignani. 2003. T cell costimulation by the hepatitis C virus envelope protein
E2 binding to CD81 is mediated by Lck. Eur. J. Immunol. 33: 455–464.
32. Muller, P., C. Renou, A. Harafa, E. Jouve, G. Kaplanski, E. Ville, J. J. Bertrand,
C. Masson, T. Benderitter, and P. Halfon. 2003. Lymph node enlargement within
the hepatoduodenal ligament in patients with chronic hepatitis C reflects the
immunological cellular response of the host. J. Hepatol. 39: 807–813.
33. Nuti, S., D. Rosa, N. M. Valiante, G. Saletti, M. Caratozzolo, P. Dellabona,
V. Barnaba, and S. Abrignani. 1998. Dynamics of intra-hepatic lymphocytes in
chronic hepatitis C: enrichment for V24 T cells and rapid elimination of ef-
fector cells by apoptosis. Eur. J. Immunol. 28: 3448–3455.
34. Abrignani, S. 1997. Bystander activation by cytokines of intrahepatic T cells in
chronic viral hepatitis. Semin. Liver Dis. 17: 319–322.
35. Fiore, G., G. Piazzolla, V. Galetta, L. Caccetta, O. Schiraldi, and S. Antonaci.
1999. Liver tissue expression of CD80 and CD95 antigens in chronic hepatitis C:
relationship with biological and histological disease activities. Microbios. 97:
29–38.
36. Burgio, V. L., G. Ballardini, M. Artini, M. Caratozzolo, F. B. Bianchi, and
M. Levrero. 1998. Expression of co-stimulatory molecules by Kupffer cells in
chronic hepatitis of hepatitis C virus etiology. Hepatology 27: 1600–1606.
37. Mochizuki, K., N. Hayashi, K. Katayama, N. Hiramatsu, T. Kanto, E. Mita,
T. Tatsumi, N. Kuzushita, A. Kasahara, H. Fusamoto, et al. 1997. B7/BB-1 ex-
pression and hepatitis activity in liver tissues of patients with chronic hepatitis C.
Hepatology 25: 713–718.
38. Grogan, J. L., M. Mohrs, B. Harmon, D. A. Lacy, J. W. Sedat, and
R. M. Locksley. 2001. Early transcription and silencing of cytokine genes un-
derlie polarization of T helper cell subsets. Immunity 14: 205–215.
39. Heile, J. M., Y. L. Fong, D. Rosa, K. Berger, G. Saletti, S. Campagnoli, G. Bensi,
S. Capo, S. Coates, K. Crawford, et al. 2000. Evaluation of hepatitis C virus
glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recom-
binant protein is superior to secreted recombinant protein and DNA-based vac-
cine candidates. J. Virol. 74: 6885–6892.
40. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by
flow cytometry. J. Immunol. Methods 171: 131–137.
41. Krutzik, P. O., J. M. Irish, G. P. Nolan, and O. D. Perez. 2004. Analysis of protein
phosphorylation and cellular signaling events by flow cytometry: techniques and
clinical applications. Clin. Immunol. 110: 206–221.
42. Krutzik, P. O., and G. P. Nolan. 2003. Intracellular phospho-protein staining
techniques for flow cytometry: monitoring single cell signaling events. Cytometry
A 55: 61–70.
43. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two
subsets of memory T lymphocytes with distinct homing potentials and effector
functions. Nature 401: 708–712.
44. Durie, F. H., T. M. Foy, S. R. Masters, J. D. Laman, and R. J. Noelle. 1994. The
role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol.
Today 15: 406–411.
45. Romagnani, S. 2000. T-cell subsets (Th1 versus Th2). Ann. Allergy Asthma Im-
munol. 85: 9–18.
46. Messi, M., I. Giacchetto, K. Nagata, A. Lanzavecchia, G. Natoli, and F. Sallusto.
2003. Memory and flexibility of cytokine gene expression as separable properties
of human TH1 and TH2 lymphocytes. Nat. Immunol. 4: 78–86.
47. Cosmi, L., F. Annunziato, M. I. G. Galli, R. M. E. Maggi, K. Nagata, and
S. Romagnani. 2000. CRTH2 is the most reliable marker for the detection of
circulating human type 2 Th and type 2 T cytotoxic cells in health and disease.
Eur. J. Immunol. 30: 2972–2979.
48. Mosmann, T. R., and K. W. Moore. 1991. The role of IL-10 in crossregulation of
TH1 and TH2 responses. Immunol. Today 12: A49–A53.
49. Moller, B., and P. M. Villiger. 2006. Inhibition of IL-1, IL-6, and TNF- in
immune-mediated inflammatory diseases. Springer Semin. Immunopathol. 27:
391–408.
50. Fehervari, Z., T. Yamaguchi, and S. Sakaguchi. 2006. The dichotomous role of
IL-2: tolerance versus immunity. Trends Immunol. 27: 109–111.
51. Jarnicki, A. G., J. Lysaght, S. Todryk, and K. H. Mills. 2006. Suppression of
antitumor immunity by IL-10 and TGF--producing T cells infiltrating the grow-
ing tumor: influence of tumor environment on the induction of CD4 and CD8
regulatory T cells. J. Immunol. 177: 896–904.
52. Zheng, S. G., J. H. Wang, J. D. Gray, H. Soucier, and D. A. Horwitz. 2004.
Natural and induced CD4CD25 cells educate CD4CD25 cells to develop
suppressive activity: the role of IL-2, TGF-, and IL-10. J. Immunol. 172:
5213–5221.
53. Tran, D. Q., H. Ramsey, and E. M. Shevach. 2007. Induction of FoxP3 expression
in naive human CD4FoxP3 T cells by T-cell receptor stimulation is transform-
ing growth factor- dependent but does not confer a regulatory phenotype. Blood
110: 2983–2990.
54. Gavin, M. A., T. R. Torgerson, E. Houston, P. DeRoos, W. Y. Ho,
A. Stray-Pedersen, E. L. Ocheltree, P. D. Greenberg, H. D. Ochs, and
A. Y. Rudensky. 2006. Single-cell analysis of normal and FoxP3-mutant human
T cells: FoxP3 expression without regulatory T cell development. Proc. Natl.
Acad. Sci. USA 103: 6659–6664.
55. Dong, C., D. D. Yang, C. Tournier, A. J. Whitmarsh, J. Xu, R. J. Davis, and
R. A. Flavell. 2000. JNK is required for effector T-cell function but not for T-cell
activation. Nature 405: 91–94.
56. Nakamura, T., Y. Kamogawa, K. Bottomly, and R. A. Flavell. 1997. Polarization
of IL-4- and IFN--producing CD4 T cells following activation of naive CD4
T cells. J. Immunol. 158: 1085–1094.
57. Kamogawa, Y., L. A. Minasi, S. R. Carding, K. Bottomly, and R. A. Flavell.
1993. The relationship of IL-4- and IFN -producing T cells studied by lineage
ablation of IL-4-producing cells. Cell 75: 985–995.
58. Unutmaz, D., P. Pileri, and S. Abrignani. 1994. Antigen-independent activation
of naive and memory resting T cells by a cytokine combination. J. Exp. Med. 180:
1159–1164.
59. Geginat, J., F. Sallusto, and A. Lanzavecchia. 2001. Cytokine-driven proliferation
and differentiation of human naive, central memory, and effector memory CD4
T cells. J. Exp. Med. 194: 1711–1719.
60. Meuer, S. C., R. E. Hussey, M. Fabbi, D. Fox, O. Acuto, K. A. Fitzgerald,
J. C. Hodgdon, J. P. Protentis, S. F. Schlossman, and E. L. Reinherz. 1984. An
alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep
erythrocyte receptor protein. Cell 36: 897–906.
61. Tacke, M., G. Hanke, T. Hanke, and T. Hu¨nig. 1997. CD28-mediated induction
of proliferation in resting T cells in vitro and in vivo without engagement of the
T cell receptor: evidence for functionally distinct forms of CD28. Eur. J. Immu-
nol. 27: 239–247.
62. Kerstan, A., and T. Hu¨nig. 2004. Cutting edge: distinct TCR- and CD28-derived
signals regulate CD95L, Bcl-xL, and the survival of primary T cells. J. Immunol.
172: 1341–1345.
63. Lagaudriere-Gesbert, C., F. Le Naour, S. Lebel-Binay, M. Billard, E. Lemichez,
P. Boquet, C. Boucheix, H. Conjeaud, and E. Rubinstein. 1997. Functional anal-
ysis of four tetraspans, CD9, CD53, CD81, and CD82, suggests a common role
in costimulation, cell adhesion, and migration: only CD9 upregulates HB-EGF
activity. Cell Immunol. 182: 105–112.
64. Delaguillaumie, A., J. Harriague, S. Kohanna, G. Bismuth, E. Rubinstein,
M. Seigneuret, and H. Conjeaud. 2004. Tetraspanin CD82 controls the associa-
tion of cholesterol-dependent microdomains with the actin cytoskeleton in T lym-
phocytes: relevance to co-stimulation. J. Cell Sci. 117: 5269–5282.
65. Romagnani, S. 1997. The Th1/Th2 paradigm. Immunol. Today 18: 263–266.
66. Baugh, J. A., and R. Bucala. 2001. Mechanisms for modulating TNF  in im-
mune and inflammatory disease. Curr. Opin. Drug Discov. Devel. 4: 635–650.
67. Kubo, M., M. Yamashita, R. Abe, T. Tada, K. Okumura, J. T. Ransom, and
T. Nakayama. 1999. CD28 costimulation accelerates IL-4 receptor sensitivity and
IL-4-mediated Th2 differentiation. J. Immunol. 163: 2432–2442.
68. Andres, P. G., K. C. Howland, A. Nirula, L. P. Kane, L. Barron, D. Dresnek,
A. Sadra, J. Imboden, A. Weiss, and A. K. Abbas. 2004. Distinct regions in the
CD28 cytoplasmic domain are required for T helper type 2 differentiation. Nat.
Immunol. 5: 435–442.
69. August, A., and B. Dupont. 1994. Activation of src family kinase lck following
CD28 crosslinking in the Jurkat leukemic cell line. Biochem. Biophys. Res. Com-
mun. 199: 1466–1473.
70. Viola, A., S. Schroeder, Y. Sakakibara, and A. Lanzavecchia. 1999. T lympho-
cyte costimulation mediated by reorganization of membrane microdomains. Sci-
ence 283: 680–682.
71. Shoemaker, J., M. Saraiva, and A. O’Garra. 2006. GATA-3 directly remodels the
IL-10 locus independently of IL-4 in CD4 T cells. J. Immunol. 176: 3470–3479.
72. Chang, H. D., C. Helbig, L. Tykocinski, S. Kreher, J. Koeck, U. Niesner, and
A. Radbruch. 2007. Expression of IL-10 in Th memory lymphocytes is condi-
tional on IL-12 or IL-4, unless the IL-10 gene is imprinted by GATA-3. Eur.
J. Immunol. 37: 807–817.
73. Sharpe, A. H., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev.
Immunol. 2: 116–126.
74. Laperche, S., N. Le Marrec, A. Girault, F. Bouchardeau, A. Servant-Delmas,
M. Maniez-Montreuil, P. Gallian, T. Levayer, P. Morel, and N. Simon. 2005.
Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV
antibodies improves the early detection of HCV infection. J. Clin. Microbiol. 43:
3877–3883.
75. Galy, O., M. A. Petit, S. Benjelloun, P. Chevallier, M. Chevallier,
P. Srivatanakul, A. Karalak, C. Carreira, N. Lyandrat, A. Essaid, et al. 2007.
Efficient hepatitis C antigen immunohistological staining in sections of normal,
cirrhotic and tumoral liver using a new monoclonal antibody directed against
serum-derived HCV E2 glycoproteins. Cancer Lett. 248: 81–88.
76. Nakamoto, Y., S. Kaneko, M. Honda, M. Unoura, J. Cheong, A. Harada,
K. Matsushima, K. Kobayashi, and S. Murakami. 1994. Detection of the putative
E2 protein of hepatitis C virus in human liver. J. Med. Virol. 42: 374–379.
77. Neri, S., D. Ierna, B. Mauceri, G. Abate, D. Cilio, F. Bordonaro, S. Calvagno,
D. Balsamo, D. Pulvirenti, O. Magliocco, et al. 2003. Can ultrasonographic find-
ings of perihepatic lymphadenopathy promote investigations to detect possible
184 COLIGATION OF CD81 AND CD28 INDUCES Th2 AND Tc2 CELLS
 at U












presence of virus C infection in non-symptomatic subjects? Hepatol. Res. 27:
124–128.
78. Ierna, D., R. A. D’Amico, S. Antoci, E. Campanile, and S. Neri. 2000. Perihe-
patic lymphadenopathy in chronic hepatitis C: a complementary diagnostic ele-
ment? J. Gastroenterol. Hepatol. 15: 783–785.
79. Wynn, T. A. 2003. IL-13 effector functions. Annu. Rev. Immunol. 21: 425–456.
80. Kodera, T., T. L. McGaha, R. Phelps, W. E. Paul, and C. A. Bona. 2002. Dis-
rupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from
embryonic death and diminishes TGF- production by fibroblasts. Proc. Natl.
Acad. Sci. USA 99: 3800–3805.
81. de Lalla, C., G. Galli, L. Aldrighetti, R. Romeo, M. Mariani, A. Monno, S. Nuti,
M. Colombo, F. Callea, S. A. Porcelli, et al. 2004. Production of profibrotic
cytokines by invariant NKT cells characterizes cirrhosis progression in chronic
viral hepatitis. J. Immunol. 173: 1417–1425.
82. Warren, A., D. G. Le Couteur, R. Fraser, D. G. Bowen, G. W. McCaughan, and
P. Bertolino. 2006. T lymphocytes interact with hepatocytes through fenestrations
in murine liver sinusoidal endothelial cells. Hepatology 44: 1182–1190.
83. Lechner, F., D. K. Wong, P. R. Dunbar, R. Chapman, R. T. Chung,
P. Dohrenwend, G. Robbins, R. Phillips, P. Klenerman, and B. D. Walker. 2000.
Analysis of successful immune responses in persons infected with hepatitis C
virus. J. Exp. Med. 191: 1499–1512.
84. Geginat, J., A. Lanzavecchia, and F. Sallusto. 2003. Proliferation and differen-
tiation potential of human CD8 memory T-cell subsets in response to antigen or
homeostatic cytokines. Blood 101: 4260–4266.
85. Kienzle, N., K. Buttigieg, P. Groves, T. Kawula, and A. Kelso. 2002. A clonal
culture system demonstrates that IL-4 induces a subpopulation of noncytolytic T
cells with low CD8, perforin, and granzyme expression. J. Immunol. 168:
1672–1681.
86. Heath, V. L., L. Showe, C. Crain, F. J. Barrat, G. Trinchieri, and A. O’Garra.
2000. Cutting edge: ectopic expression of the IL-12 receptor-2 in developing
and committed Th2 cells does not affect the production of IL-4 or induce the
production of IFN-. J. Immunol. 164: 2861–2865.
87. Nishikomori, R., R. O. Ehrhardt, and W. Strober. 2000. T helper type 2 cell
differentiation occurs in the presence of interleukin 12 receptor 2 chain expres-
sion and signaling. J. Exp. Med. 191: 847–858.
88. Larrea, E., N. Garcia, C. Qian, M. P. Civeira, and J. Prieto. 1996. Tumor necrosis
factor  gene expression and the response to interferon in chronic hepatitis C.
Hepatology 23: 210–217.
89. Torre, F., S. Rossol, N. Pelli, M. Basso, A. Delfino, and A. Picciotto. 2004.
Kinetics of soluble tumour necrosis factor (TNF)- receptors and cytokines in the
early phase of treatment for chronic hepatitis C: comparison between interferon
(IFN)- alone, IFN- plus amantadine or plus ribavirin. Clin. Exp. Immunol. 136:
507–512.
185The Journal of Immunology
 at U
niversità degli studi di M
ilano on D
ecem
ber 2, 2015
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
